ESMO 2024 preview – TIGIT gets its late-breaker
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.